Sanctuary Advisors LLC Makes New Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

Sanctuary Advisors LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,473 shares of the company’s stock, valued at approximately $372,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Teachers Retirement System of The State of Kentucky acquired a new position in TransMedics Group during the 2nd quarter worth $420,000. NewEdge Advisors LLC increased its holdings in shares of TransMedics Group by 26.0% during the 2nd quarter. NewEdge Advisors LLC now owns 10,372 shares of the company’s stock worth $1,562,000 after purchasing an additional 2,140 shares during the period. Creative Planning increased its holdings in shares of TransMedics Group by 78.3% during the 2nd quarter. Creative Planning now owns 9,173 shares of the company’s stock worth $1,382,000 after purchasing an additional 4,027 shares during the period. Algert Global LLC bought a new position in shares of TransMedics Group during the 2nd quarter worth about $2,685,000. Finally, Driehaus Capital Management LLC increased its holdings in shares of TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $3,267,557.11. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $3,267,557.11. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 64,205 shares of company stock valued at $9,981,907. 7.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on TMDX. Canaccord Genuity Group boosted their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Morgan Stanley boosted their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Robert W. Baird began coverage on shares of TransMedics Group in a report on Tuesday, September 24th. They set an “outperform” rating and a $200.00 price objective on the stock. Needham & Company LLC began coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They set a “buy” rating and a $208.00 price objective on the stock. Finally, Stephens upped their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group has an average rating of “Buy” and an average price target of $174.30.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $127.15 on Friday. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of 3,178.75 and a beta of 1.99. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $177.37. The firm’s 50-day moving average price is $153.42 and its two-hundred day moving average price is $137.48.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.14. The firm had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company’s quarterly revenue was up 117.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.03) earnings per share. On average, equities analysts predict that TransMedics Group, Inc. will post 1.22 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.